miR-34 Mimetics Modulate TP53 Pathway for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting and treating cancer based on TP53 pathway status are challenging due to the complexity of TP53 mutations and inactivation mechanisms, which affect the efficacy of cancer therapeutics.
Innovation Solution
Development of synthetic duplex microRNA mimetics and siRNA compositions targeting miR-34 and related sequences to inhibit cell division, specifically designed to modulate TP53 pathway activity by mimicking natural miR-34 sequences with single nucleotide differences, enhancing stability and target specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA sequencing of TP53 is used to predict pathway status, then mutation detection is achieved, but alternative inactivation mechanisms (deletion, silencing, viral factors) are not detected
Solution Approach 1:
The patent develops miR-34-based therapeutic compositions that can function across multiple TP53 pathway states (mutated, deleted, silenced, or virally inhibited). By targeting downstream miR-34 effectors rather than TP53 itself, the treatment achieves universal efficacy across all TP53 inactivation mechanisms, making a single therapy applicable to diverse cancer types regardless of specific TP53 pathway status
2Reliability
If synthetic duplex microRNA mimetics with single nucleotide differences are designed, then target specificity and stability are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent introduces single nucleotide differences at specific positions within the passenger strand of the synthetic duplex microRNA mimetics. This localized modification approach enhances target specificity and stability without requiring comprehensive changes throughout the entire sequence, thereby maintaining relative manufacturing simplicity while achieving improved therapeutic performance
Solution Approach 2:
The patent systematically varies single nucleotide parameters within the miR-34 sequence to optimize therapeutic efficacy. By making controlled, minimal changes to the nucleotide sequence rather than redesigning the entire molecule, the patent achieves enhanced specificity and stability while keeping manufacturing processes manageable
3Reliability
If miR-34 compositions are used to inhibit cell division, then cancer treatment efficacy is improved, but potential off-target effects on normal cells with functional TP53 pathways may occur
Solution Approach 1:
The patent employs miR-34 compositions at optimized concentrations and dosing regimens that achieve sufficient inhibition of cancer cell proliferation while minimizing exposure levels that could cause off-target effects. By applying the therapeutic agent at controlled partial doses rather than maximal levels, the patent balances efficacy with safety
Data Source
Figure 1~2D
AI summary
In one aspect, the invention generally relates to compositions comprising miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.